Safety, pharmacokinetics, and antimalarial efficacy of single-dose cabamiquine–pyronaridine combination therapy for the treatment of adults and adolescents with acute uncomplicated Plasmodium falciparum malaria (CAPTURE 1): a prospective, multicentre, open-label, phase 2a study
The Lancet Infectious Diseases·
- DOI
- 10.1016/s1473-3099(26)00233-1
- PMID
- 42462745
- PMCID
- —
- OpenAlex
- W7168757584
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The formulation offers a potential therapeutic alternative as artemisinin resistance continues to challenge current standard treatments. Subsequent research will determine appropriate pediatric dosing and confirm durability through expanded clinical testing.
Structured evidence summary
Research question
The investigation assesses whether a single administration of cabamiquine combined with pyronaridine effectively treats uncomplicated Plasmodium falciparum infections while maintaining an acceptable safety profile.
Study design
Researchers conducted a prospective, multicentre, open-label phase 2a clinical trial divided into two sequential parts.
Population and setting
Participants included individuals aged twelve to fifty-five years diagnosed with acute, uncomplicated Plasmodium falciparum monoinfection across medical facilities in four African nations.
Main findings
Treatment resulted in predominantly mild to moderate adverse reactions without any reported fatalities or severe complications. Day twenty-eight parasite clearance rates surpassed ninety percent in both evaluated dosage groups. The trial concluded additional cohorts prematurely due to unexpected drug concentration levels and advisory committee guidance regarding administration frequency.
Public-health relevance
The formulation offers a potential therapeutic alternative as artemisinin resistance continues to challenge current standard treatments. Subsequent research will determine appropriate pediatric dosing and confirm durability through expanded clinical testing.
Important limitations
The evaluation encompasses a limited number of participants allocated across two distinct treatment arms. Premature discontinuation of planned study phases restricts comprehensive pharmacokinetic analysis and extended safety monitoring. The absence of a blinded control group introduces potential observation bias.
GIDS interpretation
This record documents controlled clinical observations regarding a novel antimalarial pairing within a published academic journal. The content serves as a reference point for ongoing pharmaceutical development discussions rather than reflecting active pathogen tracking or real-world transmission patterns.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.